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The human regulatory complement component C4b-binding protein (C4BP) is a multimeric plasma protein, which regulates the classical pathway 
of the complement system. C4BP functions as a cofactor to factor I in the degradation of C4b and accelerates the decay rate of the C4b2a complex. 
Previously, we have demonstrated that monoclonal antibodies (C4-2 and 9) directed against the a’khain of C4b inhibit the binding of C4b to C4BP. 
In order to identify the structural domain of C4b that binds C4BP, proteolytic fragments of C4 were generated with trypsin and Staphylococcus 
aureus Vg protease. Sodium dodecyl sulfate polyacrylamide gel electrophoresis. immunoblotting and amino acid sequence analysis of the proteolytic 
fragments reactive with the anti-C4 mAb’s revealed that the residues Ala’38 Argz6 of the cc,-fragment of C4b are important for the interaction 
with C4BP. 
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1. INTRODUCTION 
Complement C4 is a glycoprotein with a A4, of 
189 kDa consisting of three disulfide-linked CY 
(88 kDa), P (72 kDa) and y (32 kDa) chains [l-6]. Syn- 
thesized in the liver as a 185 kDa single chain precursor 
it undergoes several modifications involving proteolytic 
excision of two intersubunit-linking peptides 171, 
sulfatation (81, glycosylation [9], and generation of a 
thiolester site in the a-chain [lo]. The proteolytic 
cleavage by Cls in the N-terminal part of the a-chain 
of C4 leads to the generation of the activation peptide 
C4a (8 kDa) and the activated component C4b 
(181 kDa). C4b contains at least two binding sites. One 
is unstable and responsible for the binding of C4b to 
antibody-Ag aggregates and to acceptor sites on cell 
surfaces [l-3]. The other binding site of C4b is stable 
and specific for C2 [4]. C2 bound to C4b will be cleaved 
by Cls, resulting in the C4b2a complex which acts as 
the C3 convertase [4]. 
A regulatory protein of the classical complement 
pathway is C4b-binding protein (C4BP), a high M, 
plasma protein [ll-141 which functions as a cofactor 
to factor 1 in the degradation of C4b and accelerates 
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the decay rate of the C4b2a-complex [13]. In addition, 
C4BP interacts with one of the plasma proteins in 
blood coagulation, the vitamin K-dependent protein S 
1151. C4BP is composed of multiple identical cr-chains 
with a M, of 70 kDa and one distinct P-chain with a M, 
of 45 kDa that are linked by disulfide bridges 
[ 11,16-201. Each of the 70 kDa subunits forms a ten- 
tacle with the N-terminus located at the periphery of 
the tentacle, whereas the C-termini are located in the 
central core of C4BP [21-241. The binding sites for 
C4b were located on the peripheral half of each tentacle 
[2 1,251, whereas one single distinct binding site for pro- 
tein S was localized near the central core [21,26] on the 
P-chain [17-201. The C4b- and heparin-binding func- 
ti’on and the factor 1 cofactor activity are located on the 
48 kDa chymotryptic fragments [23,25,27,28] of the 
70 kDa subunits of C4BP and the region of residues 
3:32-395 seemed important for the binding to C4b [29]. 
The cleavage of C4b by factor 1 and C4BP in the 
ac ’-chain of C4b leads to the generation of the in- 
termediate product, C4b ’ after the first cleavage of the 
a ’ -chain, resulting in a 70 kDa and a 16 kDa 
cq-fragment of the cu’-chain both still disulfide linked 
to the other chains (see Fig. 2). The second cleavage 
results in the excision of C4d (45 kDa (cYz)), and the 
generation of a third fragment (27 kDa ((~3)) of the 
a’-chain still disulfide linked to C4c [14]. In 1984, the 
primary structure of C4 has been revealed by examining 
a cDNA coding for C4 [34]. 
Abbreviurions: C4BP, C4b-binding protein; mAb, monoclonal an- 
tibody; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis 
Recently, we have localized the C4BP binding site on 
the @‘-chain of C4b and demonstrated that this binding 
could be inhibited by mAb’s (mAb C4-2 and 9) specific 
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for the cr’chain [30]. In this study we identified the 
epitopes of these mAb’s and concluded that the C4BP 
binding site is locahzed on the @j-fragment of C4b. 
2. EXPERIMENTAL 
Protein G-Sepharose 4 Fast Flow and a mono Q column were pro- 
ducts of Pharmacia LKB Biotechnology Inc. (Uppsala, Sweden). 
Bovine serum albumin (BSA), Tween-20, 3,3’-diaminobenzidine, 
dithiothreitol and iodoacetamide were obtained from Sigma 
Chemical Co. (St. Louis, MO). TPCK-Trypsin and Stuphylucoccus 
uureus V8 protease were from Worthington Biochemical Corpora- 
tion, NJ. Prestained molecuIar weight markers were from Bio-Rad. 
Polyvinyhdene difluoride membranes (Immobilon’“) were from 
Millipore. All other chemicals obtained were of the best grade 
available. 
2.2. Purificaiion of proteins 
C4BP was immuno-purified from a barium citrate precipitate of 
human plasma using anti-C4BP monoclonal affinity- 
chromatography as described [20,28]. Human complement C4 and 
C4b were obtained as described before [30]. All proteins appeared to 
be homogeneous as judged by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE). Protein concentra- 
tions were determined by measuring the absorbance at 280 nm using 
an extinction coefficient (l%, I cm) of 14.3, 14.1 and 8.7 for the 
purified mAb’s, C4BP and C4, respectively [24,31]. 
2.3. mAb’s 
mAb’s specific for human complement C4 (C4-2, 6, 8 and 9) and 
C4BP (CORE-6Bi) were obtained as described before [28,30]. The 
murine immunoglobulins were isolated by affinity chromatography 
on protein G-Sepharose 4 Fast Flow according to the instructions of 
the manufacturer, 
2.4. E!ectrophoretic and irnmunochernical fechniques 
SDS-PAGE was performed on 15 or 17.5% slab gels according to 
Laemmli 1321. After electrophoresis the gels were either stained with 
Coomassie brilliant blue R-250 or immunoblotted essentially as 
described by Towbin et al. [33] using a semi-dry electrophoretic 
transfer apparatus. The lmmobilon membranes were either blocked 
with 5% (w/v) nonfat dry milk in 50 m,M Tris-HCI, pH 7.4, I50 mM 
NaCI, incubated with mAb’s C4-2, 6, 8 and 9 against the &‘-chain of 
C4b and visualized with peroxidase-conjugated rabbit anti-mouse im- 
munoglobulins or stained with Cootnassie brilliant blue. 
Alternatively, a C4BP Iigand-blotting procedure was used in which 
a mixture of C4BP (5gg/ml) and anti-C4BP mAb C4BP-6B1 
(5 pg/ml) replaced the primary antibody essentially as described 
before PO]. 
2.5. C4b-C4BP binding QSSQJJ 
Microtiter plates (strip plate, Costar) were coated overnight at 4°C 
with C4, C4b or its proteolytic fragments (IO~girnl in 50 mM 
NaHCO,, pH 9.6, 50~1 per well). The wells were blocked with 3% 
(w/v) BSA in 50 mM Tris-HCf, 150 mM NaCl, pH 7.4 at room 
temperature for i h. The wells were washed 5 times with 50 mM Tris- 
HCI, I50 mM Nat?, pH 7.4 containing 0.2% (v/v) Tween-20 and in- 
cubated with varying concentrations of C4BP (0.1-4yg/ml) and 
mAb C4BP-6Bl (5 pg/ml) in 3% (w/v) BSA overnight at 4°C. The 
wells were washed 5 times and the amount of C4BP bound to C4b 
was detected with peroxidase-conjugated rabbit anti-mouse im- 
munoglobulins. 
2.6. Peptide supping by SDS-PAGE and ~~~u~obfott~ng 
Reduction of C4 (5.9 mg) was performed at room temperature 
overnight with 30 mM dithiothreitol in 0.5 M Tris-HCI, pH 8.8 con- 
taining 0.05% (v/v) Triton X-100. Alkylation was done at room 
132 
temperature for 90 min with 50 mM iodoacetamide. Reduced and 
alkylated C4 was incubated with 3% (u/w) trypsin or 2% (w~/w) S. 
u~~reus VX protease at 37°C for 2 and 1 h, respectively. The digestion 
was terminated by the addition of 2 mM DFP (final concentration) 
on ice. Each digest was separated by SDS-PAGE under reduced con- 
ditions and subsequently transferred to an lmmobilon membrane. 
The membranes were incubated with the anti-C4 mAb’s and parailel 
stained with Coo1nas5ie briiiiant blue R-250. The fragments wirh 
positive reactivity with the mAb’s were analyzed for N-terminal 
amino acid sequence. 
2.7. Amino acid sequence anal.vsis 
Amino-terminal amino acid sequence was determined with an Ap- 
plied Biosystems model 477A gas-phase sequencer using BEGIN-I 
and NORMAL-I cycles, connected to an on-line 120A PTH 
Analyzer. The proreolytic fragments ofC4 transferred to inlnlobiion 
membranes were detected by Coomassie staining, excised and placed 
on polybrene-treated precycled glass fiber filters in the sequencer as 
described by Matsudaira [35]. 
3. RESULTS AND DISCUSSION 
Our strategy for determining the structural do- 
main(s) of C4 that bind C4BP involved an enzymatical 
fragmentation of the molecule. Therefore, C4 was in- 
cubated with trypsin and S. ~UI’LJUS V8 protease at 37°C 
and subjected to SDS-PAGE under reduced conditions 
(Fig. 1). SDS-PAGE of the reduced tryptic fragments 
of C4 showed the liberation of apparent CTZ (45 kDa), 
cy3 (27 kDa) and LYE (16 kDa) fragments derived from 
the a’-chain of C4b, whereas the /?‘- and y-chains re- 
mained rather intact (Fig. IA, left). Parallel to the 
liberation of the as-fragment, several smaller 
fragments with apparent h4, of about 23 kDa (Tl), 
22 kDa (T2), 19 kDa (T3), 10 kDa (T4) and 8 kDa (T5) 
appeared. Immunoblotting analysis of the tryptic 
cleavage products of C4 with the mAb’s C4-2, 6, 8 and 
9 revealed that the mAb’s C4-2 and 9 were reactive with 
the putative &j-fragment of 27 kDa and the smaller 
tryptic fragments Tl to TS. The mAb’s C4-6 and in less 
extent C4-8 were reactive with the putative @z-fragment 
(Fig. 2A, right). The mAb’s C4-2 and 9 had previously 
been found to inhibit the interaction of C4b with 
C4BP, whereas the mAb’s C4-6 and 8 had no effect 
[30]. Under non-reduced conditions immunoblotting 
analysis of the tryptic digest of C4 revealed that the 
mAb’s C4-6 and 8 were reactive with the apparent C4d 
(or ay2) fragment and that the mAb’s C4-2 and 9 were 
recognizing the C4c fragment with an apparent M, of 
140 kDa (not shown). 
To place the tryptic fragments containing a possible 
~4BP-binding fragment within the structure of the C4 
molecule, the N-terminal amino acid sequences of the 
excised bands were determined. The N-terminal se- 
quences obtained for the fragments Tl to T5 matched 
that of the N-terminal sequence of the apparent 
cu3-fragment. It should be remarked that the tryptic 
fragments Tl and T2 could not compIetely be excised 
separately, ahhough this does not effect the sequence 
results. As representative N-terminal sequence the 
smallest fragment T5 is indicated in Table I. With the 
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Fig. 1. SDS-PAGE and immunoblotting analysis of proteolytic fragments of C4. Complement C4 was digested with trypsin (C4,; A) and S. aweus 
V8 protease (C~VX; B) as described in section 2. The digestion was inhibited by 2 mM DFP dissolved in 5070 (v/v) &mercaptoethanol and 
subsequently applied on 15% SDS-PAGE. The gels stained with Coomassie brilliant blue are shown to the left, and to the right the fragments 
transferred to lmmobilon membranes, which were analyzed with the mAb’s (~4-2, 6, 8 and 9 (5 fig/ml) directed against the al-chain of C4b. In 
addition, Immobilon membranes were stained with Coomassie brilliant blue from which relevant protein bands were excised from the membrane 
and directly applied to the cartridge of an Applied Biosystems 477A gas-phase sequencer. 
exception of the second residue (which was not deter- 
mined) this sequence is identical (Table I) to that of the 
15 N-terminal amino acids in the a’-chain of C4b [34]. 
As in 7-l 5 steps of Edman degradation of the T1/2, 
T3, T4 and T5 fragments an identical N-terminal se- 
quence was found, it seems that these fragments are 
derived from the Luj-fragment starting from Ala738. 
Since an arginine residue is present at position 737, 
where trypsin would be expected to perform en- 
zymatical cleavage of the molecule and since the ap- 
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Fig. 2. Schematic representation of C4 and its cleavage fragments. 
The Cls and factor 1 (I) cleavage sites are indicated by the arrows. 
The proposed positions for the epitopes of the different anti-C4 
mAb’s and the putative C4BP binding site are indicated. Factor 1 
cleaves two peptide bonds in the ru’-chain of C4b, giving rise to the 
C4d (or uz) fragment (45 kDa), Nhich is released from the remaining 
part of the molecule (C4c). C4c consists of two cu’-chain fragments: 
an N-terminal au,-fragment (27 kDa), and a carboxyl-terminal 
NJ-fragment (16 kDa), both linked to thed- and l-chain via disulfide 
bridges. 
parent M, of the TS fragment is about 8 kDa, it is 
reasonable to conclude that the domain of C4b 
recognized by the inhibitory mAb’s C4-2 and 9 is iden- 
tical to the N-terminal domain of the cuj-fragment of 
C4b, Ala73s through Arg826. As a consequence the 
putative C4BP-binding site is likely composed of the 
residues Ala738-Arg826. The tryptic fragment CJZ, which 
was recognized by the mAb’s C4-6 and 8 was also 
analyzed for N-terminal sequence. It demonstrated the 
N-terminal sequence indicated in Table II. This se- 
quence is identical to that of the first eleven amino 
acids (i.e., residues 961-972) after the Arg960-Va1961 
cleavage site, indicating that the epitopes for the mAb’s 
C4-6 and 8 are located on the CY~ (or C4d) fragment. As 
our apparent cu2-fragment seems to start from Va1961, it 
is likely that this fragment is a smaller derivative of the 
commonly accepted LYZ (or C4d) fragment starting from 
Thr938 [34]. No smaller tryptic fragments derived from 
the C4d-fragment were recognized by the mAb’s C4-6 
and 8. 
Trypsin-treated C4b did not demonstrate any C4BP 
binding activity in either the C4BP ligand blotting pro- 
cedure or the C4b-C4BP binding assay, while untreated 
C4BP gave good binding. Also the binding of intact 
C4BP to the C4b coated microtiter wells was not in- 
hibited by the addition of the proteolytically cleaved 
C4b digest. 
When C4b was digested with S. aureus V8 protease 
and examined under reduced conditions on SDS- 
PAGE, the cu’-chain was also predominantly shown to 
be cleaved into a 44 kDa (V8-1) fragment and a 23 kDa 
(V8-2) fragment (Fig. lB), whereas the,& and T-chains 
remained intact. Immunoblotting analysis of S. aureus 
V8 protease-treated C4b demonstrated that the mAb’s 
C4-6 and 8 were reactive with the @‘-chain and the V8-1 
fragment, whereas the mAb’s C4-2 and 9 recognized 
the al-chain and the fragment V8-2. The N-terminal se- 
quence obtained for fragment V8-2 matched that of the 
N-terminus of the &‘-chain of C4b starting from 
Ala738, indicating that the epitopes of the mAb’s C4-2 
Table I 
Sequence analysis of the tryptic C4 fragment T5 
Cycle no. PTH N-terminal sequence” 
I A A 
2 NDh L 
3 E E 
4 I I 
5 
6 b b 
7 E E 
R E E 
9 D D 
IO L 1. 
II 1 I 
12 D D 
13 E E 
14 D D 
15 D D 
’ N-terminal amino acid sequence according to Belt et al. [34]. 
b ND, not determined. 
Table II 
Sequence analysis of the tryptic Luz-fragment of C4 
Cycle no. PI-H N-terminal sequence” 
1 v V 
2 T T 
3 A .A 
4 s s 
5 D D 
6 P P 
7 L L 
8 D D 
9 T T 
10 L L 
11 G G 
a N-terminal amino acid sequence according to Belt et al. [34]. 
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and 9 are located at the N-terminal end of the a’-chain 
of C4b (Table III). No further sequence studies were 
done with fragment V8-1. The S. uureus V8 protease 
C4 fragments V8-1 and 2 did not demonstrate any 
C4BP binding abilities. To characterize the epitopes of 
the mAb’s C4-2 and 9 and thus the putative C4BP- 
binding domain in more detail, we attempted to 
prepare lower M, fragments by further proteolysis of 
the tryptic fragments of C4 with S. aureus V8 protease. 
Although indeed lower M, fragments were obtained by 
tryptic and subsequent V8 protease cleavage, these 
fragments were no longer reactive with the mAb’s. 
Recently, we reported [30] that the C4BP-binding 
site on C4b was located on the a’-chain of C4b and 
because of the observation of binding of C4BP to a 
70 kDa band in reduced C4b, which was likely to be the 
partly degraded a’-chain of C4b’ [36], we excluded the 
cud-fragment as a putative C4BP-binding fragment. 
And because C4c still demonstrated a low affinity for 
C4BP [37], in contrast with C4d, it was suggested that 
the binding site for C4BP was located at the N-terminal 
cuj-fragment of C4b and that possibly the negatively 
charged region between the residues 743 and 752 was 
important for the interaction with C4BP [30]. Utilizing 
our mAb’s C4-2 and 9 against the (Y’ -chain of C4b 
which had previously been found to inhibit the binding 
of C4BP to C4b we have now been able to identify a 
88 residue sequence with the help of the published se- 
quence of the molecule [34] at the N-terminal end of the 
ax-fragment of the C4b molecule that is involved in the 
interaction of C4b with C4BP (Fig. 2). Our ex- 
periments also suggest that both the tertiary structure 
of C4b and the linear sequence of amino acids in the 
cuj-fragment are important for a proper interaction of 
C4b with C4BP. This is demonstrated by the absence of 
any C4BP binding abilities of the cu3-fragment of C4b 
alone. Our experiments do not rule out the possibility 
that other sites (conformational or structural) in the 
CY’ -chain of C4b are also important in its interaction 
with C4BP. 
Previously, we have demonstrated that C4BP binds 
both to C4b and to the negatively charged heparin via 
its N-terminal 48 kDa chymotryptic tentacles, which 
have been shown to contain basic residues between 
Table 111 
Sequence analysis of the S. aureus V8 protease C4 fragment V8-2 
Cycle no. PTH N-terminal sequence” 
1 A A 
2 L L 
3 E E 
4 I I 
5 
6 G 6 
7 E E 
a N-terminal amino acid sequence according to Belt et al. [34]. 
short consensus repeats 1 and 2 of the a-chains of 
C4BP [28,29,38]. The C4BP binding region we have 
identified in this study contains a cluster of 7 acidic 
amino acids between the residues 744 and 752 in C4b 
that could be important for binding. This consideration 
is consistent with a previous study in which was 
demonstrated that the affinity of C4b for C4BP was 
enhanced under reduced ionic strength [37]. However, 
the importance of this negative domain alone could not 
be demonstrated with a corresponding synthetic pep- 
tide, because this peptide failed to react with the anti- 
C4 mAb’s and more important did not effect the bin- 
ding of C4BP to C4b (data not shown). In conclusion, 
the present observations allow a tentative assignment of 
the C4BP-binding site to the residues Ala738-Arg826 of 
the 771 amino acid long a-chain of C4 (Fig. 2), but a 
possible involvement of the negatively charged amino 
acids in the region Gl~‘~~-Asp’~~ remains to be 
determined. 
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